表1. 接受allo-HSCT的206例AML患者初诊时突变基因的检出情况.

基因突变	例数（%）
FLT3-ITD	26(12.6)
duCEBPA	20(9.7)
DNMT3A R882+FLT3-ITD+NPM1	14(6.8)
DNMT3A R882	14(6.8)
siCEBPA	9(4.4)
FLT3-ITD+NPM1	7(3.4)
FLT3-ITD+duCEBPA	4(1.9)
FLT3-TKD	4(1.9)
DNMT3A R882+FLT3-ITD	4(1.9)
c-kit	3(1.5)
NPM1	3(1.5)
duCEBPA+c-kit	2(1.0)
DNMT3A R882+NPM1	2(1.0)
siCEBPA+NPM1	2(1.0)
DNMT3A R882+NPM1+ FLT3-TKD	2(1.0)
FLT3-ITD+siCEBPA	1(0.5)
duCEBPA+ FLT3-TKD	1(0.5)
NPM1+ c-kit	1(0.5)
DNMT3A R882+ FLT3-TKD	1(0.5)
FLT3-TKD+ NPM1	1(0.5)
DNMT3A R882+NPM1+siCEBPA	1(0.5)
DNMT3A R882+FLT3-ITD+NMP1+c-kit	1(0.5)
DNMT3AR882+NPM1+siCEBPA+FLT3-TKD	1(0.5)
阴性组	82（39.8）

注：duCEBPA：双突变CEBPA；siCEBPA：单突变CEBPA；阴性组：未检出任何已知突变